The complexity of what Doc and his team are doing is mind

New Post Public Reply Private Reply Replies (1) Message Board
toodles
633
The complexity of what Doc and his team are doing is mind boggling, if we knew half of what it consists of that they have had to go through I'm sure most of us would have threw our hands in the air and walked away, we all want the instant gratification.

We are lucky that's not the CEO we have, sure they will be a lot of unseen bumps along the way but one thing for sure we have the man/team who can handle them.

Dalton is building this with the correct team of people (CEO,BOD) we are in the correct Industry.

The most expensive Conglomerate today trades at $342,261.00 per share, why because it has the CORRECT CEO/BOD Team running it.
Doc is building something on the same lines as this one and it doesn't happen overnight, yes I no a lot of investors have been here a long time why because all of them say they believe in Dalton, well I do but I also believe in the team he's putting together.

If all would take some time and do some hard research (wrenchman) Doc has a lot of Government Agencies he has to please to get this where it needs to be we all no how slow they are.

I'm not trying to influence anyone here if they should sell/buy more/move on or stay, that everyone has to do on there own they are the only ones who no there situation.

Myself I'm frustrated at how long its taking but I do understand also that's why I'm staying the trip to the end myself I will never sell all of my shares here because the CEO and TEAM are not people who fail this will be where your Generational Wealth comes into play years down the road, This industry will not be stopped it will have some delays along the way but that's normal.

JMO

Univec Conglomerate Inc (UNVC) Stock Research Links

UNVC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Hims & Hers Health Faces Revenue Challenges and Legal Issues

Updated Category News Views 246

Hims & Hers Revenue Challenges Amid Stock Decline In recent trading sessions, Hims & Hers Health reported notable stock fluctuations as the company unveiled a decline in revenue per customer linked to its customization of GLP-1 medications for weight loss. This announcement caused an almost 11% drop in the stock price. Impacts of Collaboration Termination This steep...

Continue Reading
Entrée Resources Reports Solid Results for Q3 2025

Updated Category News Views 166

Entrée Resources Ltd. Overview Entrée Resources Ltd. (TSX: ETG; OTCQB: ERLFF), a reputable Canadian mining company focused on the Oyu Tolgoi project, has announced its interim financial results for the third quarter of 2025. This announcement sheds light on its ongoing operations and future plans, emphasizing the company's significant role in one of the world's largest...

Continue Reading
Bucket List Wine Dinners Beckon to Los Angeles

Updated Category News Views 10

Sipping on the Extraordinary: LA Wine Soiree When was the last time you had a glass of wine that truly feels like you've unlocked a treasure chest? That's what LearnAboutWine.com is going for with their bucket list wine dinners in Los Angeles. Imagine tasting some of the world's most coveted bottles, all served with a level of polish that screams high-end dining. Led by...

Continue Reading
BioLife Solutions Enhances Growth Potential with $73 Million Sale

Updated Category News Views 68

BioLife Solutions Announces $73 Million Sale of SciSafe In a significant move aimed at reinforcing its strategic direction, BioLife Solutions, Inc. (NASDAQ: BLFS), a prominent player in the development and supply of cell processing tools and services for the cell and gene therapy market, has announced the sale of its biostorage subsidiary, SciSafe Holdings, Inc. The...

Continue Reading
Advancements in Universal Vaccine Development by Dx&Vx

Updated Category News Views 154

Innovative Pathway Towards a Universal COVID-19 Vaccine In the wake of a global resurgence of COVID-19, Dx&Vx (DXVX) is stepping up its efforts to develop a universal vaccine aimed at providing protection against all variants of the virus. With the recent acquisition of cutting-edge technology, this next-generation vaccine is set to attract significant global interest....

Continue Reading